New York State Common Retirement Fund Sells 56,140 Shares of Indivior PLC $INDV
The New York State Common Retirement Fund reduced its stake in Indivior PLC (NASDAQ:INDV) by 59.4%, selling 56,140 shares and now holding 38,400 shares valued at $926,000. This comes as several other institutional investors increased their positions in Indivior, which sees 60.33% institutional ownership. Analysts maintain a "Moderate Buy" rating with an average target price of $39.33, while company insiders have also recently purchased shares.
Jackson Creek Investment Advisors LLC Buys Shares of 60,890 Indivior PLC $INDV
Jackson Creek Investment Advisors LLC has acquired 60,890 shares of Indivior PLC (NASDAQ:INDV) for approximately $1.47 million in the third quarter. This move comes as Indivior maintains a "Moderate Buy" consensus rating from analysts, despite a recent downgrade from Zacks Research, with insiders also increasing their holdings. The specialty pharmaceutical company, focused on addiction treatments, is currently trading around $35 with a market capitalization of $4.38 billion.
Federated Hermes Inc. Makes New $8.12 Million Investment in Indivior PLC $INDV
Federated Hermes Inc. has made a new $8.12 million investment in Indivior PLC, acquiring 336,797 shares in Q3, representing 0.24% of the company. Indivior recently surpassed earnings and revenue estimates, and analysts maintain a "Moderate Buy" rating with a consensus price target of $39.33. Insider buying by two directors further indicates sustained investor interest in the specialty pharmaceutical company.
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ
Indivior Pharmaceuticals, Inc. announced its intention to report fourth-quarter and full-year 2025 financial results on February 26, 2026, at 7:00 a.m. U.S. EST. Following the release, a live webcast presentation will be hosted at 8:00 a.m. U.S. EST by CEO Joe Ciaffoni and other leadership members. Details for accessing the webcast and presentation replay are available on the company's website.
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ
Indivior Pharmaceuticals, Inc. announced it will release its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, at 7:00 a.m. U.S. EST. Following the release, CEO Joe Ciaffoni and other leadership team members will host a live webcast presentation at 8:00 a.m. U.S. EST, accessible via the company’s website. Registrants can also access the presentation telephonically.
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ
Indivior Pharmaceuticals Inc. will release its fourth quarter and full-year 2025 financial results on February 26, 2026, at 7:00 a.m. U.S. EST. Following the release, the leadership team will host a live webcast presentation at 8:00 a.m. U.S. EST, accessible via the company's website. Indivior specializes in long-acting injectable treatments for opioid use disorder.
Indivior completes redomiciliation from UK to US By Investing.com
Indivior Pharmaceuticals, Inc. has officially completed its redomiciliation from the United Kingdom to the United States, transitioning its parent company to a new Delaware corporation and renaming the former PLC to a wholly-owned subsidiary. This strategic move aims to strengthen its U.S. capital markets presence, improve potential U.S. equity indexation, simplify corporate governance, and align the company closer to U.S. public health leaders. The company, which specializes in treatments for opioid use disorder, saw its stock surge 174.98% over the past year and recently provided strong financial guidance for 2026, surpassing analyst expectations.
Indivior completes redomiciliation from UK to US
Indivior Pharmaceuticals, Inc. has completed its redomiciliation from the UK to the US, making a new Delaware corporation the parent company. This move aims to strengthen its U.S. capital markets presence and simplify corporate governance. The company's stock has surged, and it projects strong financial performance for 2026, driven by its SUBLOCADE treatment for opioid use disorder.
Indivior announces completion of redomiciliation to U.S.
Indivior has completed its redomiciliation from the United Kingdom to the United States. The company's new parent entity is Indivior Pharmaceuticals, a Delaware corporation, whose common stock is now listed on Nasdaq under the symbol "INDV." Indivior PLC has been renamed Indivior and is now a wholly-owned subsidiary.
Indivior Announces Completion of Redomiciliation to the United States
Indivior Pharmaceuticals, Inc. has completed its redomiciliation from the United Kingdom to the United States, appointing a new Delaware corporation, IPI, as its parent company. This move aims to strengthen its U.S. capital markets presence, simplify corporate governance, and enhance its position as a U.S.-based treatment innovator. Indivior's common stock will continue to trade on Nasdaq under the symbol “INDV.”
Indivior (INDV) Completes Move from UK to US, Listed on Nasdaq
Indivior Pharmaceuticals (INDV) has successfully moved its corporate headquarters from the UK to the US, establishing a new Delaware-based parent company and retaining its Nasdaq listing. The company specializes in manufacturing prescription drugs for substance use disorders and mental illnesses, with significant revenue generated in the U.S. Indivior exhibits robust financial performance with strong revenue growth and high gross margins, though its liquidity ratios and P/E and P/S ratios suggest a mixed financial outlook and potential overvaluation.
Indivior completes redomiciliation from UK to US By Investing.com
Indivior Pharmaceuticals, Inc. has officially completed its redomiciliation from the United Kingdom to the United States, with the new Delaware corporation now serving as the parent company. This strategic move aims to enhance its U.S. capital markets presence, simplify governance, and strengthen ties with U.S. public health leaders. The company also announced strong financial guidance for 2026, projecting increased net revenue and adjusted EBITDA, driven significantly by its SUBLOCADE treatment for opioid use disorder.
Indivior completes redomiciliation from UK to US
Indivior Pharmaceuticals, Inc. has completed its redomiciliation from the UK to the US, making a new Delaware corporation the parent company. This move aims to strengthen its U.S. capital markets presence, simplify governance, and align closer with U.S. public health leaders, as the company specializes in treatments for opioid use disorder. Indivior's stock has surged 174.98% over the past year, and recent financial guidance for 2026 surpassed analyst expectations, driven by strong growth projections for its SUBLOCADE treatment.
Indivior Announces Completion of Redomiciliation to the United States
Indivior Pharmaceuticals, Inc. has completed its redomiciliation from the United Kingdom to the United States, making a new Delaware corporation, IPI, the parent company. Indivior PLC is now Indivior Ltd. and a wholly-owned subsidiary of IPI. This move is expected to strengthen Indivior's U.S. capital markets presence, simplify corporate governance, and further position it as a U.S.-based treatment innovator.
Indivior Announces Completion of Redomiciliation to the United States
Indivior Pharmaceuticals, Inc. announced the completion of its redomiciliation from the United Kingdom to the United States, making a new Delaware corporation, IPI, the parent company. The company believes this change will strengthen its U.S. capital markets presence, simplify corporate governance, and enhance its position as a U.S.-based treatment innovator. IPI's common stock will continue to trade on Nasdaq under the symbol "INDV," and shareholders of the former Indivior PLC received one new IPI common share for each ordinary share held.
Indivior PLC: Can a Focused Addiction-Treatment Portfolio Power the Next Wave of Growth?
Indivior PLC is focusing on addiction medicine, particularly opioid use disorder, with a strategy centered on buprenorphine-based therapies, long-acting injectables, and a diversifying pipeline. The company aims to differentiate itself from generics and competitors like Alkermes and Camurus by emphasizing clinical specialization, adherence-driven outcomes, and alignment with public health priorities. Indivior's future valuation and stock performance depend on its ability to transition its portfolio towards higher-margin, differentiated treatments and prove their effectiveness in improving patient outcomes.
Indivior (NASDAQ:INDV) Downgraded to "Hold" Rating by Zacks Research
Zacks Research has downgraded Indivior (NASDAQ:INDV) from a "Strong-Buy" to a "Hold" rating, although the consensus among analysts remains a "Moderate Buy" with an average target price of $34.57. Indivior recently surpassed earnings expectations, reporting an EPS of $0.72 against a $0.38 consensus and revenues of $314 million, exceeding the $257.66 million estimate. Insider activity shows a trend of accumulation, with two directors purchasing 775 shares each in early January, contributing to a total of 4,871 shares acquired by insiders in the last three months.
Indivior PLC: How a Specialist Addiction Franchise Is Quietly Rebuilding a Global Pharma Contender
Indivior PLC is focusing on addiction therapeutics, leveraging long-acting injectables and digital support to differentiate itself in the market. The company aims to address the opioid crisis and other addictions by providing a curated portfolio of buprenorphine-based therapies like SUBLOCADE, supported by a pipeline targeting broader addiction and psychiatric indications. This strategy, centered on system-level design, specialized focus, and defensible technology, positions Indivior to grow its market share despite strong competition and past legal challenges, as reflected in its stock performance.
51,426 Shares in Indivior PLC $INDV Purchased by KLP Kapitalforvaltning AS
KLP Kapitalforvaltning AS initiated a new position in Indivior PLC (NASDAQ:INDV) by purchasing 51,426 shares valued at approximately $1.24 million in the third quarter. Other major institutional investors, including Goldman Sachs, Geode Capital Management, and Rubric Capital Management, also significantly increased their holdings in the company. Indivior recently surpassed quarterly EPS and revenue projections, and analysts generally maintain a "Buy" rating with an average price target of $34.57.
Take the Zacks Approach to Beat the Markets: Indivior, FIGS & Ulta Beauty in Focus
Despite recent market volatility, U.S. stock markets ended last week positively, with the Nasdaq, Dow, and S&P 500 seeing healthy gains. Zacks Research highlights several key achievements in guiding investors, including strong performance from Indivior and FormFactor following Zacks Rank upgrades, significant advances for FIGS and Five Below after recommendation upgrades, and impressive returns from Zacks Focus List stocks like Huntington Ingalls and Ulta Beauty. The article also showcases the success of Zacks' ECAP, ECDP, and Top 10 Stock portfolios in outperforming the market and mitigating risk.
Naloxone Market Is Going to Boom |EMERGENT, Indivior PLC, Akorn, Inc
The Naloxone Market is projected to grow significantly, from USD 1,483.8 Mn in 2025 to USD 3,005.7 Mn by 2032, at a CAGR of 10.6%. This growth is driven by rapid innovation, rising investment, and shifting regional dynamics. The report by Coherent Market Insights provides a detailed analysis of market segmentation, key players, regional coverage, and strategic insights for decision-makers.
Indivior PLC (INDV) Announces Full-Year 2026 Financial Guidance
Indivior PLC (INDV) has released its full-year 2026 financial guidance, projecting total net revenue between $1.125 billion and $1.195 billion, with SUBLOCADE® net revenue expected to be $905 million to $945 million. The company anticipates an 11% growth in SUBLOCADE net revenue and a 35% increase in adjusted EBITDA for 2026, following a "transition year" in 2025. Indivior also highlighted its recent inclusion in the S&P SmallCap 600® index and a planned domicile change from the U.K. to the U.S.
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug
Monte Rosa Therapeutics (GLUE) saw its stock jump 45% after announcing positive interim data from a Phase I study for its inflammation drug candidate, MRT-8102. The drug showed robust activity, achieving significant NEK7 degradation and reducing key inflammatory markers like hsCRP and IL-6, with a favorable safety profile. The company plans further studies for MRT-8102 and other pipeline candidates in 2026.
Indivior PLC Provides 2026 Financial Guidance and Business Update
Indivior PLC has released its financial guidance for 2026, projecting total net revenue between $1,125 million and $1,195 million. The company expects SUBLOCADE net revenue to grow by 11% to $905-$945 million and anticipates a 35% increase in Adjusted EBITDA, reaching $535-$575 million. Additionally, Indivior PLC plans to change its domicile from the U.K. to the U.S. by January 26, 2026.
Indivior PLC Announces Full-Year 2026 Financial Guidance and Business Highlights
Indivior PLC has released its financial guidance for 2026, projecting total net revenue between $1.125 billion and $1.195 billion, with anticipated SUBLOCADE net revenue of $905 million to $945 million. The company expects adjusted EBITDA in the range of $535 million to $575 million, driven by accelerated SUBLOCADE dispense unit growth and operational efficiencies achieved through its Action Agenda. Additionally, Indivior has been included in the S&P SmallCap 600 index and plans to transition its domicile to the U.S. in January 2026.
Indivior Provides Full-Year 2026 Financial Guidance and Business Update
Indivior PLC announced its full-year 2026 financial guidance, projecting total net revenue between $1,125 million and $1,195 million and SUBLOCADE net revenue between $905 million and $945 million. The company expects significant margin expansion with adjusted EBITDA hitting $535 million to $575 million, representing a 35% growth, driven by accelerated SUBLOCADE dispense units and a simplified operating model from its "Indivior Action Agenda." Indivior also highlighted recent milestones including its inclusion in the S&P SmallCap 600® index and a pending change of domicile to the U.S.
Indivior director Stejbach buys $27,429 in shares
Indivior PLC director Mark Stejbach acquired 775 shares of the company's stock on January 5, 2026, for a total of $27,429. This purchase, made at $35.3926 per share, was part of a Non-Executive Director Purchase Plan where stock was received in lieu of cash for director fees. Following this transaction, Stejbach directly owns 16,847 ordinary shares of Indivior PLC.
Ryan Barbara, Indivior director, buys $27,429 in shares
Ryan Barbara, a director at Indivior PLC (EXCHANGE:INDV), recently purchased 775 ordinary shares for $27,429 as part of a Non-Executive Director Purchase Plan. This insider transaction follows strong company performance, including exceeding Q3 2025 earnings expectations, resolving a DOJ matter with a $295 million payment, and ongoing positive clinical trial results for its drug SUBLOCADE. Despite shares nearing a 52-week high and appearing slightly overvalued by P/E ratio, analysts maintain a "Strong Buy" consensus.
Indivior director Stejbach buys $27,429 in shares By Investing.com
Indivior PLC director Mark Stejbach purchased 775 shares of the company's stock for $27,429 on January 5, 2026, as part of a Non-Executive Director Purchase Plan. This transaction increased his direct ownership to 16,847 ordinary shares. The announcement comes after recent positive news for Indivior, including strong Q3 2025 earnings, a significant payment to resolve a U.S. Department of Justice matter, and ongoing plans to re-domesticate to Delaware.
New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations
A new study published in JAMA Network Open by Indivior PLC found that monthly maintenance doses of SUBLOCADE® (extended-release buprenorphine) rapidly reduced opioid use and improved abstinence in individuals with moderate-to-severe opioid use disorder. Both 100-mg and 300-mg doses were well-tolerated, with post-hoc analyses suggesting the higher 300-mg dose was significantly more effective for patients with high-frequency fentanyl use. These findings highlight extended-release buprenorphine as a valuable treatment approach, especially in the context of the current opioid crisis.
Indivior outlines $1.03B–$1.08B 2025 revenue guidance and cost structure overhaul through action agenda
Indivior has provided revenue guidance for 2025, projecting between $1.03 billion and $1.08 billion, along with an expected adjusted operating profit margin of 21-23%. This outlook is part of a broader "Action Agenda" aimed at overhauling its cost structure and enhancing profitability. The company expects to achieve $25-$35 million in annual savings by 2026 through this initiative.
Indivior PLC stock: volatile swings, legal overhangs and a nervous market mood
Indivior PLC's stock has experienced volatile swings due to fresh legal developments, shifting earnings expectations, and past opioid litigation, causing its share price to dip below its 52-week peak. The market is split between investors seeking value and those wary of ongoing legal risks and competitive pressures in the addiction treatment market. Future performance will depend on the trajectory of legal costs, competitive dynamics, and capital allocation strategies.
Suboxone Market is Going to Booming Growth 2025 With Top Key
The global Suboxone market is projected to experience significant growth, reaching an estimated value of US$ 6,163.9 million in 2022 and exhibiting a CAGR of 4.0% during the forecast period (2022-2030). A recent report by Coherent Market Insights forecasts substantial growth for the market from 2025 to 2032, driven by increasing industry demand, expanding applications, and continuous technological advancements. The report offers a comprehensive analysis of market size, revenue trends, key growth factors, drivers, restraints, challenges, opportunities, and competitive strategies, providing actionable insights for businesses.
INDIVIOR PLC (NASDAQ:INDV) Presents a High-Growth Momentum and Technical Breakout Setup
INDIVIOR PLC (NASDAQ:INDV) has been identified as a strong candidate for investors due to its high-growth momentum profile and favorable technical setup for a potential breakout. The company exhibits robust earnings growth, consistent analyst estimate beats, positive analyst revisions, and strong cash flow generation. Technically, INDV shows a forceful uptrend, market outperformance, and is currently in a bull flag consolidation pattern, suggesting a good entry point.
Indivior PLC: Opioid-treatment specialist tests investor nerves as volatility returns
Indivior PLC's stock has experienced significant volatility due to ongoing legal and regulatory challenges, despite a positive long-term outlook in addiction treatment. Investors are weighing these risks against the company's strong fundamentals and resilient revenue growth. Wall Street analysts are cautiously constructive, indicating a balanced risk-reward profile, with further clarity on litigation needed for a more decisive upward re-rating.
Indivior PLC Announces Inclusion in S&P SmallCap 600 Index
Indivior PLC announced its inclusion in the S&P SmallCap 600 index on December 22, 2025, a move that aligns with the company's U.S. business focus. This inclusion places Indivior's shares within an index that tracks small-cap companies with market capitalizations ranging from $1.2 billion to $8.0 billion. The company aims to further grow its SUBLOCADE® treatment for opioid use disorder.
Indivior Announces Inclusion in the S&P SmallCap 600® Index
Indivior PLC (Nasdaq: INDV) has announced its inclusion in the S&P SmallCap 600® index, effective December 22, 2025. This inclusion signifies an important milestone for the company, aligning its capital markets presence with its U.S. business profile, especially concerning its SUBLOCADE® treatment for opioid use disorder. The S&P SmallCap 600 index measures the performance of small-cap companies in the U.S. equities market with market capitalization between $1.2 billion and $8.0 billion.
Indivior (NasdaqGS:INDV): Reassessing Valuation After Positive SUBLOCADE and INDV-2000 Clinical Trial Results
Indivior recently shared positive clinical data for SUBLOCADE and Phase II results for INDV-2000, leading to a significant increase in its share price. While the stock's 35.5x P/E ratio suggests it's overvalued compared to the industry average, a Discounted Cash Flow model indicates potential undervaluation. Investors are currently paying a premium, anticipating high future earnings growth for the pharmaceutical company.
Indivior approves executive salary increases for senior leadership
Indivior's board has approved executive salary increases for its CEO and CFO, effective January 1, 2026, following a competitive market review. CEO Joseph Ciaffoni's salary will increase to $1,115,000, and CFO Ryan Preblick's to $604,000, aims to retain senior leadership. The company's stock, INDV, currently has a Hold rating from analysts with a $40.00 price target.
The Bull Case For Indivior (INDV) Could Change Following New SUBLOCADE Fentanyl-User Efficacy Data
Indivior (INDV) recently released positive clinical trial results for SUBLOCADE®, demonstrating its efficacy in reducing opioid use and supporting abstinence, particularly among high-frequency fentanyl users. This enhanced effectiveness, especially with the 300-mg dose, strengthens the investment narrative for Indivior's core product. While the impact is medium-term, it supports future demand and pricing, alongside immediate catalysts like 2025 revenue guidance and a sole Nasdaq listing.
Indivior (INDV) Is Up 8.9% After Newtyn Ups Stake And EBITDA Guidance Rises - Has The Bull Case Changed?
Indivior (INDV) saw an 8.9% rise after Newtyn Management increased its stake and the company raised its full-year adjusted EBITDA guidance by 15%. This surge is attributed to strong SUBLOCADE-driven revenue growth and planned cost-saving initiatives, leading investors to re-evaluate its investment narrative. While the stock has risen sharply and trades at richer multiples, high leverage and a new leadership team remain points of focus.
Indivior stock hits all-time high at 37.72 USD
Indivior PLC's stock has reached an all-time high of $37.72, reflecting a 209.43% increase over the past year and 149.61% in six months, largely attributed to strong market performance and investor confidence. The company also reported impressive Q3 2025 earnings, surpassing analyst expectations, and has settled a legacy matter with the U.S. Department of Justice. Indivior is also moving forward with a shareholder vote on re-domestication to Delaware and has presented positive research on its SUBLOCADE treatment.
Indivior stock hits all-time high at 37.72 USD By Investing.com
Indivior PLC's stock reached an all-time high of 37.72 USD, marking a significant 209.43% increase over the past year and 149.61% in six months, reflecting strong investor confidence. The company reported impressive Q3 2025 earnings, surpassing analyst expectations, and successfully settled a $295 million obligation with the U.S. Department of Justice. Indivior also plans a shareholder vote on re-domestication to Delaware and presented positive research on its SUBLOCADE treatment for opioid use disorder.
Why One Value Fund Has a $101 Million Bet on Indivior Stock Amid a 212% Surge
New York City-based Newtyn Management significantly increased its stake in Indivior PLC, adding nearly 1.6 million shares in the third quarter. This move brings their total investment in Indivior to $101.3 million, making it their top holding and accounting for 12.4% of the firm's U.S. equity assets. The increase reflects both active purchasing and the stock's price appreciation.
Why One Value Fund Has a $101 Million Bet on Indivior Stock Amid a 212% Surge
New York City-based Newtyn Management significantly increased its stake in Indivior PLC, adding nearly 1.6 million shares and making it the fund's largest holding valued at $101.3 million. This strategic investment comes as Indivior's stock has surged 212% over the past year, far outpacing the S&P 500. The move reflects Newtyn's conviction in Indivior's turnaround, evidenced by strong growth in SUBLOCADE sales and strategic operational resets expected to generate substantial annual savings.
Indivior stock hits all-time high of 33.72 USD
Indivior PLC's stock has reached an all-time high of $33.72, showing a significant increase of 197.95% over the past year. This surge is attributed to strong investor confidence, healthy gross profit margins, and anticipated net income growth. The company also recently surpassed analyst expectations for Q3 2025 earnings and settled a $295 million obligation with the U.S. Department of Justice.
Indivior Concludes Legacy U.S. Department of Justice Matter
Indivior PLC announced it has concluded its legacy U.S. Department of Justice (DOJ) matter by paying the outstanding obligation of $295 million in full. This payment was sourced from Indivior's cash on hand and results in the termination of the resolution agreement with the DOJ. The company's CEO, Joe Ciaffoni, stated that this milestone removes a significant liability and simplifies their capital structure.
Indivior Concludes Legacy U.S. Department of Justice Matter
Indivior PLC announced it has fully concluded its legacy U.S. Department of Justice (DOJ) matter by paying the outstanding $295 million obligation. This payment terminates the resolution agreement with the DOJ and was funded using Indivior's cash on hand. The company states this removes a significant liability and simplifies its capital structure, reinforcing its commitment to integrity and compliance.
Indivior PLC Proposes Re-Domiciliation to Delaware
Indivior PLC announced a proposal to re-domicile from the U.K. to Delaware, U.S., establishing Indivior Pharmaceuticals, Inc. as the new holding company. This move aims to enhance its U.S. capital market presence and simplify governance, with shareholders scheduled to vote on the proposal on December 11, 2025. If approved, shares of the new U.S. entity will replace Indivior's current shares on Nasdaq, aligning with its predominantly U.S.-based shareholder base.
Indivior PLC (INDV) Beats Q3 Earnings and Revenue Estimates
Indivior PLC (INDV) reported Q3 earnings of $0.72 per share, surpassing the Zacks Consensus Estimate of $0.38 and beating earnings from the previous year. The company's revenues for the quarter reached $314 million, exceeding the consensus estimate by 20.81%, showing a strong performance against earlier expectations. Indivior's shares have significantly outperformed the S&P 500 year-to-date, and current estimates suggest the stock will perform in line with the market in the near future.
